These findings suggest that CMT-U27 is a valuable comparative model, particularly for mechanistic studies and targeted drug screening involving the HER2 and Wnt pathways, but should be used in combination with human breast cancer models to validate the findings prior to clinical translation, due to significant interspecies and specific biological limits. This evidence concerns the gene ERBB2 and breast cancer.